Atherosclerosis Treatment Drugs Market by Drug Type (Statins, PCSK9 Inhibitors, Fibrates, Bile Acid Sequestrants, Omega-3 Fatty Acids, Antiplatelet Drugs), by Mechanism of Action (Lipid-Lowering Agents, Anti-Inflammatory Agents, Antithrombotic Agents), by Administration Type (Oral Medications, Injectable Medications), by End-Use Industry (Hospitals, Clinics, Homecare); Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Atherosclerosis Treatment Drugs Market was valued at USD 10.4 billion in 2023 and will surpass USD 21.3 billion by 2030; growing at a CAGR of 10.8% during 2024 - 2030. The atherosclerosis treatment drugs market is witnessing significant growth owing to the increasing prevalence of cardiovascular diseases, rising cholesterol-related disorders, and the growing adoption of advanced treatment options. Atherosclerosis, a chronic inflammatory condition characterized by plaque buildup in arteries, remains a major cause of heart attacks, strokes, and peripheral vascular diseases worldwide. The demand for effective therapeutic solutions is being propelled by advancements in drug development, improved patient awareness, and increasing investments in healthcare infrastructure. Innovative therapies targeting lipid levels, inflammation, and thrombosis are reshaping the landscape of atherosclerosis management. Key players in the market are focusing on introducing combination therapies and novel drug mechanisms to enhance treatment outcomes. With an aging population and unhealthy lifestyles contributing to cardiovascular risks globally, the market for atherosclerosis treatment drugs is anticipated to grow steadily in the coming years. Statins Segment is Largest Owing to Established Efficacy in Lipid-Lowering Therapy The statins segment holds the largest market share in the atherosclerosis treatment drugs market owing to their established role as first-line lipid-lowering agents for managing high cholesterol levels. Statins, including atorvastatin, rosuvastatin, and simvastatin, effectively reduce low-density lipoprotein (LDL) cholesterol and lower the risk of cardiovascular events such as heart attacks and strokes. Their widespread use in primary and secondary prevention of cardiovascular diseases underscores their dominance in the market. Statins are favored for their cost-effectiveness, proven clinical benefits, and well-documented safety profile. They are commonly prescribed in both hospital and outpatient settings, driving their demand across healthcare facilities globally. Additionally, increasing recommendations from international health organizations, such as the American Heart Association and the European Society of Cardiology, for the use of statins in high-risk patients further solidify their position as the largest drug type segment. Anti-Inflammatory Agents is Fastest Growing Owing to Emerging Role in Atherosclerosis Management The anti-inflammatory agents segment is the fastest growing mechanism of action in the market as research increasingly highlights the role of inflammation in the development and progression of atherosclerosis. Unlike traditional lipid-lowering therapies, anti-inflammatory drugs target underlying inflammatory pathways to reduce arterial plaque buildup and improve cardiovascular outcomes. This innovative approach has gained traction with the introduction of therapies such as canakinumab and emerging investigational drugs. Growing clinical evidence showing the effectiveness of anti-inflammatory agents in reducing cardiovascular risks, even in patients with controlled cholesterol levels, has fueled interest in this segment. As healthcare providers seek complementary therapies for managing atherosclerosis, the demand for anti-inflammatory agents is expected to surge, particularly in patients with residual inflammatory risk despite statin therapy. Injectable Medications is Fastest Growing Administration Type Due to Improved Patient Adherence The injectable medications segment is the fastest growing administration type in the atherosclerosis treatment drugs market. This growth is primarily driven by the increasing adoption of biologics such as PCSK9 inhibitors, including evolocumab and alirocumab, which are administered via injection. Injectable drugs offer the advantage of high efficacy, particularly for patients who are statin-intolerant or require additional lipid-lowering therapy to achieve cholesterol targets. The convenience of long-acting injectable formulations, which reduce the frequency of dosing, has significantly improved patient adherence and treatment outcomes. Moreover, advancements in drug delivery technologies, including prefilled syringes and auto-injectors, have enhanced the accessibility and ease of administration for patients. As demand grows for alternative options to oral medications, injectable therapies are expected to play an increasingly important role in atherosclerosis management. Hospitals Segment is Largest Owing to Comprehensive Patient Management and Specialized Care The hospitals segment dominates the end-use industry in the atherosclerosis treatment drugs market due to the availability of advanced diagnostic tools, specialized medical care, and access to a wide range of therapeutic options. Hospitals serve as primary healthcare providers for patients with severe cardiovascular conditions requiring immediate intervention and long-term disease management. The ability to monitor complex cases, perform surgical interventions, and provide multidisciplinary care makes hospitals a key segment in this market. Hospitals are increasingly adopting integrated treatment approaches, including lipid management, anti-inflammatory therapies, and antithrombotic drugs, to address the multifaceted nature of atherosclerosis. The presence of specialized cardiology departments, access to injectable therapies, and growing investment in cardiovascular disease research contribute to the continued dominance of hospitals in this market. Additionally, increasing hospital admissions for cardiovascular events drive demand for atherosclerosis treatment drugs in these settings. North America is Largest Region Owing to High Prevalence of Cardiovascular Diseases North America holds the largest share of the atherosclerosis treatment drugs market, driven by the high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and robust adoption of innovative therapies. The United States, in particular, accounts for a significant portion of the market, with rising incidences of obesity, diabetes, and hypercholesterolemia contributing to the growing burden of atherosclerosis. Favorable reimbursement policies, widespread access to statins and advanced injectable therapies, and a strong pipeline of novel drugs further support market growth in the region. Additionally, government initiatives to reduce cardiovascular mortality and increased investments in research and development drive advancements in treatment options. The presence of leading pharmaceutical companies and their focus on launching new therapies position North America as the largest regional market for atherosclerosis treatment drugs. Competitive Landscape and Leading Companies The atherosclerosis treatment drugs market is highly competitive, with leading pharmaceutical companies focusing on expanding their product portfolios and developing innovative therapies to address unmet medical needs. Key players in the market include Pfizer Inc., Amgen Inc., Sanofi S.A., Novartis AG, and AstraZeneca PLC. These companies are investing heavily in research and clinical trials to introduce next-generation lipid-lowering agents, anti-inflammatory therapies, and combination treatments. The competitive landscape is shaped by increasing demand for biologics, patient-centric drug delivery systems, and advanced therapies targeting multiple pathways involved in atherosclerosis. Strategic collaborations, mergers, and acquisitions are common strategies adopted by major players to enhance their market presence. As companies focus on addressing statin intolerance, residual cardiovascular risk, and treatment adherence challenges, the market is expected to witness significant advancements and growth opportunities. Recent Developments: • Pfizer Inc. launched a new combination drug for atherosclerosis treatment that combines a statin with a PCSK9 inhibitor for enhanced cholesterol-lowering efficacy. • Merck & Co., Inc. received FDA approval for its latest PCSK9 inhibitor, which offers improved efficacy in reducing LDL cholesterol levels in patients with high cardiovascular risk. • Amgen Inc. introduced a new injectable monoclonal antibody to treat atherosclerosis, targeting the inflammation in arterial walls and reducing the risk of heart attacks and strokes. • Sanofi S.A. announced the expansion of its portfolio with the launch of a new omega-3 fatty acid-based drug to help lower triglyceride levels in atherosclerosis patients. • Novartis AG initiated a clinical trial for a novel fibrate drug aimed at reducing atherosclerosis progression and improving heart health in patients with high cholesterol levels. List of Leading Companies: • Pfizer Inc. • Merck & Co., Inc. • Amgen Inc. • Sanofi S.A. • Novartis AG • AbbVie Inc. • AstraZeneca plc • Eli Lilly and Co. • Boehringer Ingelheim GmbH • GlaxoSmithKline plc • Johnson & Johnson • Takeda Pharmaceutical Company Limited • Bristol-Myers Squibb Company • Regeneron Pharmaceuticals, Inc. • Mylan N.V. (Viatris Inc.) Report Scope: Report Features Description Market Size (2023) USD 10.4 Billion Forecasted Value (2030) USD 21.3 Billion CAGR (2024 – 2030) 10.8% Base Year for Estimation 2023 Historic Year 2022 Forecast Period 2024 – 2030 Report Coverage Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments Segments Covered Atherosclerosis Treatment Drugs Market by Drug Type (Statins, PCSK9 Inhibitors, Fibrates, Bile Acid Sequestrants, Omega-3 Fatty Acids, Antiplatelet Drugs), by Mechanism of Action (Lipid-Lowering Agents, Anti-Inflammatory Agents, Antithrombotic Agents), by Administration Type (Oral Medications, Injectable Medications), by End-Use Industry (Hospitals, Clinics, Homecare) Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) Major Companies Pfizer Inc., Merck & Co., Inc., Amgen Inc., Sanofi S.A., Novartis AG, AbbVie Inc., Eli Lilly and Co., Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Mylan N.V. (Viatris Inc.) Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements